Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 10/20 | 0.43 |
| ▸ | CDK2 | P24941 | 10/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 5/20 | 0.43 |
| ▸ | CDK4 | P11802 | 5/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.43 |
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999065 | 1.00 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2647588 | 1.00 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL999066 | 1.00 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2647811 | 0.99 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2647815 | 0.99 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2649344 | 0.91 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2650481 | 0.91 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2650478 | 0.91 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2649343 | 0.91 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL999233 | 0.91 | CCNE1 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | CCNE1 2454/4885CDK2 253/4885CCNE2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.